The BIOKÉ webshop is closed until January 2nd, 2019. We wish you a successful 2019!
The new 16-well model uses a proprietary noninvasive biosensor technology to quantify cell proliferation, morphology changes, and adhesion in a label-free, real-time manner. The new 16-well model uses a proprietary noninvasive biosensor technology to quantify cell proliferation, morphology changes, and adhesion in a label-free, real-time manner.
SAN DIEGO (PRWEB) JULY 31, 2018 - ACEA Biosciences, is a privately owned biotechnology company which develops cutting edge instrumentation for cell analysis. The company has just introduced the xCELLigence RTCA S16, which the ideal entry level model for exploratory studies in cell biology.
Controlled and monitored via an external computer, the S16can be placed in any standard CO2 tissue culture incubator. The user friendly RTCA software allows for real-time control and monitoring of cell biology in action, and displays real-time kinetic data with a plethora of analysis functions. Indeed, the system can monitor the impact of new drugs, viruses, bacteria, and co-culture assays, making the system ideal for studies in new drug discovery, vaccine development, and immunotherapy.
“We are moving away from the iPad-based iCELLigence platform because Apple’s continuous and frequent iOS upgrades have been causing compatibility issues with our RTCA software,” explained Jeff Xue, Ph.D., Marketing Director at ACEA Biosciences. “The new S16 model is a PC Windows-based platform ideal for assay development and optimization. Users can run one 16-well plate on the S16 instead of two 8-well plates,” added Dr. Xue. “The S16 model is compatible with ACEA’s existing E-Plate® 16, E-Plate View 16, and E-Plate 16 PET.”
ACEA’s xCELLigence RTCA instruments are being used in both academia and industry for life science applications ranging from cancer immunotherapy, bacterial biofilms, vaccine development and cardiotoxicity testing. With the xCELLigence technology, scientists can non-invasively monitor the behavior of cells by quantifying cell proliferation, morphology change, and attachment quality in a label-free, real-time manner.
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,500 instruments have been placed globally, and have been used in more than 1,800 peer-reviewed publications, which can be viewed in a searchable library at the website of ACEA.